2000至2019年美国毒物中心报告的单物质曲唑酮暴露
该研究回顾性分析了2000年1月1日至2019年12月31日美国国家毒物数据系统(NPDS)报告的单物质曲唑酮暴露病例。共纳入118,773例进行人口学与照护级别分析,59.5%无需医疗住院;81,698例有明确医疗结局的病例中,最常见临床效应为轻-中度中枢神经系统抑制(49.7%)、QTc延长(2019年病例中占12.2%)、呕吐(9.0%)、低血压(7.0%)和心动过速(7.0%)。接受治疗并从中急诊科离院者中位摄入剂量为600 mg,入住ICU者为1500 mg;医疗结局从中位剂量600 mg(无效应)至1500 mg(主要效应)呈剂量-反应关系。心脏相关临床效应及心脏特异性干预需求总体少见。
要点
- 118,773例单物质曲唑酮暴露中,59.5%的病例无需医疗住院。
- 81,698例有明确医疗结局者中,轻-中度中枢神经系统抑制最常见(49.7%),QTc延长在2019年病例中占12.2%。
- 接受治疗并从中急诊科离院者中位摄入剂量为600 mg,入住ICU者为1500 mg。
- 医疗结局中位摄入剂量从无效应者的600 mg至主要效应者的1500 mg,呈剂量-反应关系。
- 心脏相关临床效应及心脏特异性干预需求总体少见。
适用人群与场景
- 2000年1月1日至2019年12月31日向美国国家毒物数据系统(NPDS)报告的单物质曲唑酮暴露病例。
研究设计与关键结果
- 研究类型:对NPDS报告的单物质曲唑酮暴露的回顾性审查;纳入118,773例进行人口学与照护级别分析,其中81,698例有明确医疗结局。
- 59.5%的病例无需医疗住院。
- 有明确医疗结局的81,698例中,最常见临床效应为轻-中度中枢神经系统抑制(49.7%)、QTc延长(2019年病例中占12.2%)、呕吐(9.0%)、低血压(7.0%)、心动过速(7.0%)。
- 接受治疗并从中急诊科离院者中位摄入剂量为600 mg,入住ICU者为1500 mg。
- 医疗结局中位摄入剂量从无效应者的600 mg至主要效应者的1500 mg。
- 心脏相关临床效应及心脏特异性干预需求总体少见。
- 照护级别与医疗结局均存在剂量-反应关系。
证据类型、等级与局限
- 证据类型:回顾性审查(基于美国国家毒物数据系统报告)。
- 局限:原文未报告局限性
对床旁实践的改变
- 多数曲唑酮暴露因需住院罕见且大部分病例无效应或仅有轻微效应,可被归类为低严重度。
- 摄入剂量与所需照护级别及医疗结局存在剂量-反应关系,中位剂量600 mg对应急诊科治疗并离院,1500 mg对应ICU入住或主要效应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Individual case reports describe trazodone overdose resulting in QTc prolongation and cardiac arrhythmias. The clinical effects and outcomes associated with trazodone exposures on a large-scale basis are less well known.
OBJECTIVE: The primary objective was to characterize the severity of single substance trazodone exposures and identify any relationships that may exist between dose of trazodone and severity of exposure. The secondary objective was to describe these exposures from a demographic and clinical symptom standpoint.
METHODS: A retrospective review of single-substance trazodone exposures reported to the National Poison Data System (NPDS) from 1 January 2000 to 31 December 2019 was performed. The primary objective was to characterize the severity of trazodone exposures and relationships between ingested dose and level of care required or medical outcome.
RESULTS: A total of 118,773 cases were included in the analysis of demographics and level of care required. A majority (59.5%) of cases did not require medical admission. Of the 81,698 cases with known medical outcomes, the most common clinical effects included mild-moderate CNS depression (49.7%), QTc prolongation (12.2% of cases in 2019), vomiting (9.0%), hypotension (7.0%), and tachycardia (7.0%). The median ingested dose associated with treatment, and release from the emergency department was 600 mg compared to 1500 mg in those admitted to the intensive care unit (ICU). Regarding medical outcome, median ingested dose ranged from 600 mg in those experiencing no effect to 1500 mg in those experiencing major effects. Cardiac-related clinical effects and the need for cardiac-specific interventions were overall infrequent. A dose-response relationship was identified for level of care and medical outcome.
CONCLUSIONS: Many trazodone exposures can be characterized as low severity due to the infrequent need for healthcare facility admission and large proportion of cases that experienced no effects or only minor effects.
参考来源
- Husak N, Leonard JB, Seung H, et al. Single-substance trazodone exposures reported to US poison centers from 2000 to 2019. Clin Toxicol (Phila). 2022. PMID: 35475757. doi:10.1080/15563650.2022.2068423
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。